Desloratadine
- Generic Name
- Desloratadine
- Brand Names
- Aerius, Clarinex, Clarinex-D, Neoclarityn, Desloratadine ratiopharm, Desloratadine Teva, Desloratadine Actavis, Dasselta, Azomyr
- Drug Type
- Small Molecule
- Chemical Formula
- C19H19ClN2
- CAS Number
- 100643-71-8
- Unique Ingredient Identifier
- FVF865388R
- Background
Desloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.
- Indication
For the relief of symptoms of seasonal allergic rhinitis, perennial (non-seasonal) allergic rhinitis. Desloratidine is also used for the sympomatic treatment of pruritus and urticaria (hives) associated with chronic idiopathic urticaria.
- Associated Conditions
- Allergic Rhinitis (AR), Asthma, Chronic Idiopathic Urticaria, Common Cold, Nasal Congestion, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis, Nasal symptoms, Non-nasal symptoms
- Associated Therapies
- Antihistamine
Chronic Spontaneous Urticaria Market Expected to Reach $36 Billion by 2035 as Novel Targeted Therapies Transform Treatment Landscape
• The global chronic spontaneous urticaria (CSU) market is projected to grow from $15.1 million in 2024 to $36 billion by 2035, driven by rising diagnosis rates and innovative biologic therapies.
• Pharmaceutical giants including Novartis, Sanofi, Roche, and AstraZeneca are advancing promising treatments beyond traditional antihistamines, with BTK inhibitors like remibrutinib and rilzabrutinib showing significant potential in clinical trials.
• Treatment paradigms are shifting from conventional approaches toward personalized medicine and targeted therapies, offering new hope for the approximately 2.8 million CSU patients across major markets who often experience inadequate symptom control.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath